Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMI-1359 in Healthy Adult Subjects
NCT02931214Phase 1Completed
- Sponsor
- GlycoMimetics
- Start
- Aug 2016
- Primary completion
- Oct 2017
- Modality
- Bivalent/Multivalent Binders, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute myeloid leukemia (AML), breast cancer and prostate cancer (PCa) comparing GMI-1359 Arm with Placebo Arm (2 arms). Primary endpoint: Treatment related adverse events at 15 days. Started Aug 2016; status: completed.
02
Drugs
GMI-1359
03
Conditions
acute myeloid leukemia (AML)breast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT02931214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02931214.